Ebos Group has a history of solid growth and consistently improving its return on capital employed (ROCE), according to Morgans, and record in-line 1H results didn't disappoint.

The broker upgrades its FY24 and FY25 forecasts by around 1% and raises its target to $44.12 from $43.75.

Management offered no specific guidance for FY23 though expects another full year of profitable growth.

The broker's Add rating is maintained for Ebos Group, which is considered suitable for those investors seeking sustainable medium-term returns.

Sector: Health Care Equipment & Services.

Target price is $44.12.Current Price is $40.78. Difference: $3.34 - (brackets indicate current price is over target). If EBO meets the Morgans target it will return approximately 8% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2023 Acquisdata Pty Ltd., source FN Arena